Diminished mobility due to multiple sclerosis

Fampridine (4-aminopyridine in a long-acting form) has been shown to improve walking in patients with multiple sclerosis, and can have a modest effect on cognitive function. It increases the conduction speed in demyelinated nerves. Fampridine is prescribed by an expert, who reviews the patient after 8 weeks to see if the drug has been effective. The usual dose is: